Baclofen Setback Forces Sun R&D Arm Towards Difficult Choices

 
• By Anju Ghangurde

Sun Pharma Advanced Research Company’s baclofen GRS has failed to meet its primary endpoint in a US Phase III study, posing several tough questions for the firm. It may have to advance partnering plans for some assets and also review its cash flow situation closely.

Paths
SPARC MAY HAVE TO MAKE SOME TOUGH CHOICES IN VIEW OF THE STUDY SETBACK

More from R&D

More from Scrip